Diagnostic utility of positronic emission tomography in recurrences of prostate cancer


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

An analysis of national and foreign literature dedicated to recurrence of prostate cancer, is presented in the article. The diagnostic utility of positronic emission tomography, fused with computer tomography and magnetic resonance tomography in case of biochemical recurrences of prostate cancer is discussed.

Full Text

Restricted Access

About the authors

N. V Petrovskiy

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: N_Petrovskiy@hotmaiI.com

P. V Glybochko

FGAOU VO I.M. Sechenov First Moscow State Medical University

M. B Dolgushin

FGBU N.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of Russia; FGBU N.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of Russia

G. E Krupinov

FGAOU VO I.M. Sechenov First Moscow State Medical University

M. A Shariya

FGBU National Medical Research Center of Cardiology of Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia (Sechenov University)

N. A Meshcheryakova

FGBU N.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of Russia

References

  1. Miller Е.Т., Salmasi А., Reiter R.E. Anatomic and Molecular Imaging in Prostate Cancer - Copyright. Cold Spring Harbor Laboratory Press. 2017: 1-25.
  2. GLOBOCAN 2012 (IARC), Cancer Incidence and Mortality Worldwide, Section of Cancer Surveillance, http://gIobocan.iarc. fr/ (доступ от 21/03/2015).
  3. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). М.: ФГБУ «МНИОИим. П.А. Герцена» МинздраваРоссии. 2014: 250
  4. National Cancer Institute, Surveillance Epidemiology and End Results. SEER Stat Fact Sheets: Prostate. http://seer.cancer.gov/statfacts/htmI/ prost.html (доступ от 21/03/2015).
  5. Асланиди И.П., Пурсанова Д.М., Мухортова О.В., Сильченков А.В., Рощин Д.А., Корякин А.В., Иванов С.А., Широкорад В.И. ПЭТ/КТ с 11С-холином в диагностике рецидива рака предстательной железы у пациентов с биохимическим прогрессированием. Онкоурология. 2015;3:79-86
  6. Алексеев Б.Я., Нюшко К.М., Крашенинников А.А., Сафронова Е.Ю., Сергиенко С.А., Калпинский А.С., Воробьев Н.В., Каприн А.Д. Методы диагностики и лечения олигометастазов у больных раком предстательной железы с прогрессированием заболевания после проведенного радикального лечения. Онкоурология. 2016;2(12):64-73
  7. Freedland S.J., Presti Jr. J.C., Amling C.L. et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. UroIogy. 2003;61:736-741.
  8. Chism D.B., Hanlon A.L., Horwitz E.M. et al. A comparison of the single and doubIe factor high-risk modeIs for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J. Radiat Oncol Biol Phys. 2004;59:380-385.
  9. Mottet N., Bastian P. J., Bellmunt J., van de Burgh R.C.N.,Bolla M., van Casteren N.J. et al. EAU guidelines on prostate cancer. Update 2014. European Association of Urology. Available at: http://www.uroweb.org/ guideIines/onIineguideIines/.
  10. Глыбочко П.В., Аляев Ю.Г., Терновой С.К., Григорьев Н.А., Безруков Е.А., Морозов С.П., Лачинов Э.Л., Мартиросян Г.А. Диагностика местного рецидива рака простаты после радикальной простатэктомии: нативнаяэндоректальная МРТ и эндоректальная МРТ с динамическим контрастированием. Медицинский вестник Башкортостана. 2013;2(8):249-256
  11. Огнерубова И.Н., Поддубная И.В., Матвеев В.Б. Значение ультрачувствительного метода количественного определения простатического специфического антигена в диагностике рецидива рака предстательной железы. Современная онкология. 2012;4:50-52
  12. Bolton D.M., Ta A., Bagnato M., Muller D., Lawrentschuk N.L., Severi G., Syme R.R., Giles G.G. Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer. World J. Urol. 2014;32:431-435.
  13. Гришина Ю.А., Хмелевский Е.В. Лучевая терапия локальных рецидивов рака предстательной железы после радикальной простатэктомии. Вопросы онкологии. 2015;1:7-13.
  14. Сивков А.В., Муравьев В., Кешишев Н.Г., Шадеркин И.А., Шкабко О.В. Спасительные методы лечения рака предстательной железы после радикальной терапии. Экспериментальная и клиническая урология. 2010;4:10-16
  15. Mottet N., Bellmunt J., Briers E., van den Bergh R.C.N., Bolla M., van Casteren N.J., Cornford R., Culine S., Joniau S., Lam T., Mason M.D., Matveev V., van der Poel H., van der Kwast T.H., Rouviere O., Wiegel T. Guidelines on prostate cancer. Eur. Urol. 2015;137.
  16. NationaI Comprehensive Cancer Network. NCCN CIinicaI Practice Guidelines in Oncology: Prostate Cancer Version 2.2018; 3. Available online: https://www.nccn.org/professionaIs/physician_gIs/PDF/ prostate. pdfJager.
  17. Рыбалов М.А., Аль-Шукри С.Х., Боровец С.Ю. Современные методы визуализации рецидивов рака предстательной железы и перспективы их развития. Урологические ведомости. 2015;1:7-10
  18. Богушевич Е.В., Демешко П.Д., Красный С.А., Ролевич А.И. Возможности различных методов медицинской визуализации в диагностике причин биохимического рецидива после радикальной простатэктомии по поводу рака предстательной железы. Онкологический журнал. 2009;1:65-71
  19. Dotan Z.A., Bianco F.J. et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. JCO. 2005;23(9):1962-1968.
  20. Kane C.J., Amling C.L., Johnstone P.A. et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 2003; 61(3): 607-611.
  21. Kosuri S., Akhtar N.H., Smith M., Osborne J.R., Tagawa S.T. Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostatespecific membrane antigen radioimmunotherapy. Adv Urol. 2012; Article ID 921674, 8 pages.
  22. Olsson A.Y., Bjartell A., Lilja H., Lundwall A. Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. Int J. Cancer. 2005;113(2):290-297.
  23. Galgano S.J. Valentin R. McConathy J.Role of РЕТ imaging for biochemical recurrence following primary treatment for prostate cancer. Translational Andrology and Urology. 2018; 7(Supp I. 4): S462-S476.
  24. Fortuin A., Rooij M., Zamecnik P. et al. Molecular and functional imaging for detection of lymph node metastases in prostate cancer. Int J. Mol Sci. 2013;14:13842-13875.
  25. Лишманов Ю.Б., Чернова В.И. Национальное руководство по радионуклидной диагностике. Томск: SST. 2010: 418
  26. Das C.J., Razik A., Sharma S. Positron emission tomography in prostate cancer: An update on state of the art. Indian J. Urol. 2018;34(3):172-179.
  27. Eiber M., Rauscher I., Souvatzoglou М., Maurer Т. Prospective head-to-head comparison of 11C-choIine-PET/MR and 11C-choIine-PET/CT for restaging of biochemical recurrent prostate cancer. Eur J. NucI Med Mol Imaging. 2017;44:2179-2188.
  28. Freitag M.T., Radtke J.P., Afshar-Oromieh A. et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in (68) Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. Eur J Nucl Med Mol Imaging. 46. 201744:776-787.
  29. Joshi A., Mehawed G., Rhee H., Pryor D. The clinical efficacy of PSMA РЕТ/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities-results of a multicentre, prospective clinical trial. BJU International. 2018;122(Suppl. 2):11-12.
  30. Kranzbtihler B., Nagel H., Becker A.S. et al. Clinical performance of (68)Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy. Eur J. Nucl Med Mol Imaging. 2018;45:20-30.
  31. Gabriele D., Collura D., Oderda M. et al. Is there still a role of computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database. World J. Urol. 201634(4):517-523.
  32. Beheshti M., Haim S., Zakavi R. et al. Impact of 18 F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J. Nucl Med. 2013;54:833-840.
  33. Rybalov M., Breeuwsma A.J., Leliveld A.M. et al. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11CCholine positron emission tomography in recurrent prostate cancer. World J. Urol. 2013;31(2):319-23.
  34. Treglia G., Ceriani L., Sadeghi R. et al. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/ CT in restaging prostate cancer patients: a meta-analysis. Clin Chem Lab Med. 2014;52(5):725-733.
  35. Von Eyben F.E., Kairemo K. Meta-analysis of (11)C-choline and (18) F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun. 2014;35:221-230.
  36. Fanti S., Minozzi S., Castellucci P. et al. PET/CT with (11C-choline for evaluation of prostate cancer patients with biochemical recurrence: metaanalysis and critical review of available data. Eur J. Nucl Med Mol Imaging. 2016;43:55-69.
  37. Evangelista L., Zattoni F., Guttilla A. et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and metaanalysis. Clin Nucl Med. 2013;38:305-314.
  38. Evangelista L., Cimitan M., Hodolic M. et al. The ability of 18F-choline PET/CT to identify local recurrence of prostate cancer. Abdom Imaging. 2015;40:3230-3237.
  39. Fortuin A.S., Deserno W.M., Meijer H.J. et al. Value of PET/CT and MR lymphography in treatment of prostate cancer patients with lymph node metastases. Int J. Radiat Oncol Biol Phys. 2012;84:712-718.
  40. Kitajima K., Murphy R.C., Nathan M.A.et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J. Nucl Med. 2014;55:223-232.
  41. Zaman M.U., Fatima N., Zaman A. et al. Diagnostic challenges in prostate cancer and 68Ga-PSMA PET imaging: a game changer? Asian Pacific J. Cancer Prev. 201718(10):2625-2528.
  42. Долгушин М.Б., Мещерякова Н.А., Оджарова А.А., Матвеев В.Б., Невзоров Д.И., Платонова О.Е., Кочергин П.В. Позитронная эмиссионная томография, совмещенная с компьютерной томографией, с F-ПСМА-1007 в диагностике рецидива рака предстательной железы: клиническое наблюдение. Онкоурология. 2018;3(14):134-138
  43. Леонтьев А.В., Рубцова Н.А., Халимон А.И., Кулиев М.Т., Пылова И.В., Лазутина Т.Н., Хамадеева Г.Ф., Алексеев Б.Я., Костин А.А., Каприн А.Д. Применение радиомеченыхлигандов к простатспецифическому мембранному антигену для определения локализации биохимического рецидива рака предстательной железы методом ПЭТ/КТ (обзор литературы). Медицинская визуализация. 2018;3(22):81-97.
  44. Rajasekaran A.K., Anilkumar G., Christiansen J.J. Is prostate-specific membrane antigen a multifunctional protein? Am J. Physiol Cell Physiol. 2005;288(5):C975-81.
  45. Giesel F.L., Hadaschik B., Cardinale J. et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44(4):678-688
  46. Cho S.Y., Gage K.L., Mease R.C. et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a lowmolecular-weight inhibitor of prostatespecific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53(12):1883-1891
  47. Szabo Z., Mena E., Rowe S.P. et al. Initial evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)- targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17(4):565-574.
  48. Ahmadzadehfar H., Eppard E., Ktirpig S. et al. The rapeuticresponseandside effects of repeated radio ligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7(11):12477-12488.
  49. Kratochwil C., Giesel F.L., Stefanova M. et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. J. Nucl Med. 2016;57(8):1170-1176.
  50. Cardinale J., Schafer M., Benesova M. et al. Preclinical evaluation of [18F] PSMA1007: a new PSMA-ligand for prostate cancer imaging. J. Nucl Med 2016; 58(3):425-431.
  51. Rowe S.P., Macura K.J., Ciarallo A. et al. Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naive and Castration-Resistant Metastatic Prostate Cancer. J Nucl Med. 2016;57:46-53.
  52. Koerber S.A., Will L., Kratochwil C., Haefner M.F. 68Ga-PSMA-11 РЕТ/ CT in primary and recurrent prostate carcinoma: Implications for radio therapeutic management in 121 patients. Journal of Nuclear Medicine. 2019; 60(2): 234-240.
  53. Budaus L., Leyh-Bannurah S.R., Salomon G. et al. Initial Experience of (68) Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur Urol. 2016;69:393-396.
  54. Afshar-Oromieh A., Avtzi E., Giesel F.L., et al. The diagnostic value of PET/CT imaging with the (68)Galabelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.
  55. Eiber M., Maurer T., Souvatzoglou M. et al. Evaluation of Hybrid 6SGa-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med. 2015;56:668-674.
  56. Caroli P., Sandler I., Matteucci F., De Giorgi U68Ga-PSMA РЕТ/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. European Journal of Nuclear Medicine and Molecular Imaging. 2018;45(12): 2035-2044.
  57. England J.R., Paluch J., Ballas L.K., Jadvar H. 18F Fluciclovine РЕТ/CT Detection ofRecurrent Prostate Carcinoma in Patients With Serum PSA № 1 ng/mL After Definitive Primary Treatment. Clinical nuclear medicine. 2019; 44(3): e128- e132.
  58. Nanni C., Zanoni L., Pultrone C. et al. (18)F-FACBC (anti1-amino-3-(18) F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial. Eur J Nucl Med Mol Imaging. 2016;43:1601-1610.
  59. Calais J., Fendler W.P., Herrmann K. et al. Comparison of (68)Ga-PSMA-11 and (18)F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence. J Nucl Med. 2018;59:789-794.
  60. Wibmer A.G., Burger I.A., Sala E. et al. Molecular Imaging of Prostate Cancer. Radiographics. 2016;36:142-159.
  61. Mansi R, Fleischmann A, Macke HR, et al. Targeting GRPR in urological cancers-from basic research to clinical application. Nat Rev Urol 2013;10:235-244.
  62. Mansour N., Paquette M., Ait-Mohand S. et al. Evaluation of a novel GRPR antagonist for prostate cancer PET imaging: [(64)Cu]-DOTHA(2)-PEG-RM26. Nucl Med Biol. 2018;56:31-38.
  63. Mitran B., Thisgaard H., Rosenstrom U. et al. High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26. Contrast Media Mol Imaging. 2017;2017:68736-68784.
  64. Wieser G., Popp I., Christian Rischke H. et al. Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist (68)GaRM2: Preliminary results in patients with negative or inconclusive [(18)F]Fluoroethylcholine-PET/CT. Eur J Nucl Med Mol Imaging. 2017;44:1463-1472.
  65. Lehman M., Kahkonen E., Jambor I., Kemppainen J. et al. In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res. 2013;19:5434-5443.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies